• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Senzime

3.88 SEK+1.57 %20/7 17:29
Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.57 %
-12.02 %
-29.45 %
-24.66 %
-28.15 %
-33.68 %
-26.38 %
-83.68 %
-34.62 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
609.99M SEK
Turnover
1M SEK
Revenue
104.02M
EBIT %
-117.84 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29/10
2026

Interim report Q3'26

18/2
2027

Annual report '26

22/4
2027

Interim report Q1'27

Regulatory press release2026-07-16 08:00

Interim report Q2 2026: Strong sensor sales and improved margins, despite continued U.S. monitor market headwinds

Senzime
Regulatory press release2026-07-16 08:00

Delårsrapport Q2 2026: Stark sensorförsäljning och förbättrade marginaler trots fortsatt utmanande marknadsförhållanden i USA för nyförsäljning av monitorer

Senzime
Regulatory press release2026-07-15 21:00

Senzime och Philips Medical Systems ingår långsiktigt partnerskap för utveckling och kommersialisering

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-07-15 21:00

Senzime and Philips Medical Systems enter development and commercialization partnership

Senzime
Press release2026-07-13 12:00

Inbjudan till presentationer av Senzimes rapport för andra kvartalet 2026

Senzime
Press release2026-07-13 12:00

Invitation to presentations of Senzime’s second quarter 2026 report

Senzime
Press release2026-06-29 09:00

Senzimes TetraGraph-system erhåller ANVISA godkännande i Brasilien

Senzime
Press release2026-06-29 09:00

Senzime’s TetraGraph system receives ANVISA regulatory approval in Brazil

Senzime
Press release2026-06-05 10:00

Senzime presenterar utökade TetraGraph-funktioner genom lanseringen av TetraAnalytics på Euroanaesthesia 2026

Senzime
Press release2026-06-05 10:00

Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026

Senzime
Press release2026-06-03 11:45

Senzime stärker sin position inom barnanestesi genom att teckna ytterligare sjukhusavtal och lyfta fram positiv utfallsdata

Senzime
Press release2026-06-03 11:45

Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data

Senzime
Press release2026-06-01 11:00

Senzime stärker erbjudandet inom hållbar anestesi med lansering av ny EMG-sensor

Senzime
Press release2026-06-01 11:00

Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor

Senzime
Press release2026-05-27 11:15

Senzime erhåller FDA 510(k)-godkännande för utökade funktioner i TetraGraph-systemet

Senzime
Press release2026-05-27 11:15

From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system

Senzime
Regulatory press release2026-05-19 17:45

Kommuniké från årsstämma i Senzime AB (publ)

Senzime
Regulatory press release2026-05-19 17:45

BULLETIN FROM ANNUAL GENERAL MEETING IN SENZIME AB (PUBL)

Senzime
Press release2026-04-30 09:52

Analyst Group: Analyst Group intervjuar Senzimes VD Philip Siberg

Senzime
Press release2026-04-29 14:15

Senzime förstärker den amerikanska verksamheten och ledningsgruppen

Senzime